预约演示
更新于：2025-12-09
Epidermal growth factor cancer vaccine(Center of Molecular Immunology)
表皮生长因子癌症疫苗(Center of Molecular Immunology)
更新于：2025-12-09
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)临床2/3期 |
特殊审评- |
登录后查看时间轴
关联
19
项与 表皮生长因子癌症疫苗(Center of Molecular Immunology) 相关的临床试验RPCEC00000457
Safety and efficacy of CIMAvax-EGF® in patients with moderate-severe chronic obstructive pulmonary disease (COPD) compared to usual pharmacological treatment in the controlled phase of the disease. Phase II/III controlled clinical trial - COPD-VAX
RPCEC00000445
Evaluation of biomarkers associated with the clinical effect of the CIMAvax-EGF® vaccine in patients with advanced stages of non-small cell lung cancer (NSCLC). Exploratory Study of Biomarkers - EMA-Lung
NCT06011772
A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
100 项与 表皮生长因子癌症疫苗(Center of Molecular Immunology) 相关的临床结果
登录后查看更多信息
100 项与 表皮生长因子癌症疫苗(Center of Molecular Immunology) 相关的转化医学
登录后查看更多信息
100 项与 表皮生长因子癌症疫苗(Center of Molecular Immunology) 相关的专利（医药）
登录后查看更多信息
30
项与 表皮生长因子癌症疫苗(Center of Molecular Immunology) 相关的文献（医药）2025-06-01PATHOLOGY RESEARCH AND PRACTICE
Vaccination and personalized cancer vaccines focusing on common cancers in women: A narrative review
Review
作者: Mahdigholi, Fateme-Sadat ; Ghahfarrokhi, Seyed Sadeq Mousavi ; Karimi, Pegah ; Haji Abdolvahab, Mohadeseh
Immunotherapy has recently cast great attention on cancer vaccines in order to aim to decrease tumor growth, elicit persistent anti-tumor memory, and avert adverse reactions. Moreover, cancer vaccines employ tumor antigens to stimulate anti-tumor immunity using different platforms, for example, whole cells, nucleic acids, peptides, etc. Recent findings have classified cancer vaccines into cell-based, virus-based, peptide-based, and nucleic acid-based types. Personalized cancer vaccines, also known as neoantigens, have exhibited acceptable safety and efficacy in eliciting immune responses against melanoma and glioblastoma. Neoantigen-based vaccines, concentrating on tumor antigens present only in cancer cells, bring intriguing opportunities for different types of cancer, including melanoma, lung, bladder, breast, renal, head and neck, and colorectal cancers. Furthermore, breast cancer research underscores ongoing trials of vaccines targeting α-lactalbumin to prevent the recurrence of triple-negative breast cancer. Lung cancer studies have discovered interesting outcomes with liposomal vaccines and the potential of CIMAvax-EGF in the prevention of lung cancer. Studies on ovarian cancer highlight personalized cancer vaccines using dendritic cells and various tumor-associated antigens to elicit T-cell responses against cancer cells. Overall, such advancements suggest great promise for future clinical translation of cancer novel immunotherapy-based approaches to effectively counter various types of cancer.
2023-01-01Journal of Cancer
Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
Article
作者: Lamadrid García, Janet ; Rodríguez Machado, Jorge ; Flores Rodríguez, Justo E ; Crombet Ramos, Tania ; Gracia Medina, Elias A ; Elejalde Larrinaga, Ángel ; Corrales Otero, Danay ; Inguanzo Valdés, Iris B ; Ropero Toirac, Ramón ; Flores Vega, Yoanna I ; Páramo González, Diana L ; Alsina Tul, Luis E ; Alsina Sarmiento, Sofía C
Introduction: In Cuba, lung cancer represents the first cause of mortality for both sexes. Non-small cell lung cancer (NSCLC) is the most prevalent histology. Overall, 75-85% of NSCLC overexpress EGFR and its ligands. EGFR overexpression has been implicated in the malignant transformation by promoting cell proliferation and survival. CIMAvax-EGF is a therapeutic vaccine composed of recombinant-human EGF conjugated to a carrier protein and Montanide as an adjuvant. CIMAvax-EGF is intended to induce antibodies against self-EGF that block the EGF-EGFR interaction. Objectives: To characterize the efficacy and safety of CIMAvax-EGF as maintenance in NSCLC patients treated in the real-world setting. Results: 106 patients diagnosed with advanced NSCLC at the National Institute of Oncology and Radiobiology, who had at least stable disease after first-line therapy, were enrolled in the study. The initial four CIMAvax-EGF doses were administered every 2 weeks and then, patients received monthly re-immunizations. Globally, 52.8% of the patients were 65 years or older, 77.4% had an ECOG 1 and 62.3% had an adenocarcinoma. The median survival time (MST) was 14.6 months. Patients younger than 65 years had a MST of 16.7 months and subjects with ECOG 0 survived for 29 months. The median progression-free survival was 8.16 months. Overall, 36.8% and 19.8% of patients maintained disease control at 6 and 12 months, respectively. The most frequent adverse events were pain (27.3%) or induration (7.3%) at the injection site and local erythema (10.9%). Conclusion: CIMAvax-EGF, as an EGF depleting immunotherapy used as switch-maintenance was safe and effective in patients with NSCLC.
2021-12-01Journal of Cancer Research and Clinical Oncology
Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients
Article
作者: Qian, Qijun ; Yang, Xintao ; Lou, Jinxing ; Fang, Yuan ; Zhang, Zhiwei ; Chu, Wenqi ; Jin, Zhenlin ; Zhang, Yajun ; Wang, Pei ; Ding, Yongmei ; Wang, Jiangtao
PURPOSE:
This phase I clinical trial is designed to assess the safety and feasibility of the epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) T-cell generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer (NSCLC) patients. Compared to viral systems, the piggyBac transposon system is a simpler, more economical, and alternative way to introduce chimeric antigen receptor (CAR) transgenes into T cells.
METHODS:
This study recruited nine patients with advanced relapsed/refractory EGFR-positive NSCLC for two cycles of the piggyBac-generated EGFR-CAR T cells at dose of 1 × 106 cells/kg or 3 × 106 cells/kg of body weight. The patients were monitored for adverse events, clinical response, and persistence of plasma GFR-CAR T cells.
RESULTS:
Infusions of piggyBac-generated EGFR-CAR T cells were well tolerated in all nine patients. The most common adverse events were grade 1 to 3 fever and there were no patients who experienced grade 4 adverse events or serious cytokine release syndrome. After treatment, eight of nine patients showed detectable EGFR-CAR T cells in their peripheral blood. One patient showed a partial response and lasted for more than 13 months, while six had stable disease, and two had progressed disease. The progression-free survival of these nine patients was 7.13 months (95% CI 2.71-17.10 months), while the median overall survival was 15.63 months (95% CI 8.82-22.03 months).
CONCLUSION:
This Phase I clinical trial revealed that the non-viral piggyBac transposon system-engineered EGFR-CAR T-cell therapy is feasible and safe in treatment of EGFR-positive advanced relapsed/refractory NSCLC patients. Future study will assess it in more patients or even possibly with a higher dose. Trial registration number NCT03182816.
27
项与 表皮生长因子癌症疫苗(Center of Molecular Immunology) 相关的新闻（医药）2025-12-05
·今日头条
临床结果疫苗临床3期
2025-12-03
2025-11-07
免疫疗法细胞疗法疫苗临床结果
100 项与 表皮生长因子癌症疫苗(Center of Molecular Immunology) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 表皮生长因子癌症疫苗(Center of Molecular Immunology) | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 结直肠癌 | 古巴 | - | 2008-06-01 |
| 非小细胞肺癌 | 古巴 | - | 2008-06-01 |
| 前列腺癌 | 古巴 | - | 2008-06-01 |
| 胃癌 | 古巴 | - | 2008-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 26 | 願築齋製構夢積選構憲(鏇餘衊積艱構衊餘鏇淵) = 獵鑰積鬱選襯膚鹹選壓 醖窪簾鹽網齋觸醖遞鑰 (獵獵網餘觸膚選鏇簾遞 ) | 积极 | 2024-07-24 | |||
N/A | - | 顧夢夢獵鹹淵蓋願鹹積(糧醖範廠顧網醖觸範憲) = 齋襯選獵築齋餘顧築觸 觸夢淵遞繭積艱糧網鹹 (簾鏇構鏇窪膚鏇壓簾積 ) | 积极 | 2023-12-05 | |||
placebo | 顧夢夢獵鹹淵蓋願鹹積(糧醖範廠顧網醖觸範憲) = 鹽夢齋膚網鹹糧繭鹹鏇 觸夢淵遞繭積艱糧網鹹 (簾鏇構鏇窪膚鏇壓簾積 ) | ||||||
NEWS 人工标引  | N/A | 405 | (肺鳞癌) | 鬱齋鹹範壓鑰窪醖鬱製(積憲襯鑰鏇憲顧醖糧膚) = 餘鬱構窪願築觸範鹹鏇 網壓簾範衊鑰鬱廠選壓 (醖糧範膚鏇淵衊網蓋選 ) | 积极 | 2023-11-28 | |
最佳支持治疗 (肺鳞癌) | 鬱齋鹹範壓鑰窪醖鬱製(積憲襯鑰鏇憲顧醖糧膚) = 蓋齋鬱選獵夢選選壓積 網壓簾範衊鑰鬱廠選壓 (醖糧範膚鏇淵衊網蓋選 ) | ||||||
临床2期 | 晚期非小细胞肺癌 二线 | 21 | 鏇鑰鹹鬱範觸鏇夢築齋(鑰獵壓鹹膚願糧夢淵願) = 築醖獵積壓鬱齋積網窪 願網壓獵糧遞鏇簾憲鏇 (構獵壓膚廠鏇淵糧膚簾, 14 ~ 45) 更多 | 积极 | 2023-05-31 | ||
( PD-L1 expression ≥1% ) | 鏇鑰鹹鬱範觸鏇夢築齋(鑰獵壓鹹膚願糧夢淵願) = 壓醖襯餘廠顧憲築顧齋 願網壓獵糧遞鏇簾憲鏇 (構獵壓膚廠鏇淵糧膚簾, 12 ~ 63) 更多 | ||||||
N/A | 非小细胞肺癌 维持 | 106 | 簾獵襯襯簾積蓋鏇鏇積(積選鏇鏇遞鏇膚憲積顧) = 觸廠窪廠鹹製壓鑰築憲 網鹽淵襯蓋遞憲繭鬱繭 (餘積築壓範繭願鹽構糧, 10.6 ~ 18.8) 更多 | 积极 | 2023-01-01 | ||
(< 65-year) | 簾獵襯襯簾積蓋鏇鏇積(積選鏇鏇遞鏇膚憲積顧) = 網積醖鑰襯壓鹽夢繭艱 網鹽淵襯蓋遞憲繭鬱繭 (餘積築壓範繭願鹽構糧, 2.2 ~ 31.1) | ||||||
临床4期 | 741 | (EGF concentrations <870 pg/mL) | 鬱淵顧積簾窪鹹淵繭鹹(觸鹹網夢衊窪鹹簾製鬱) = 糧糧顧淵襯膚憲鹹顧襯 衊壓鹹齋構蓋範築衊淵 (鬱願選鏇糧艱鏇餘簾廠 ) 更多 | - | 2022-09-10 | ||
(EGF concentrations ≥870 pg/mL) | 鬱淵顧積簾窪鹹淵繭鹹(觸鹹網夢衊窪鹹簾製鬱) = 構鹽夢願餘膚製鹽鏇積 衊壓鹹齋構蓋範築衊淵 (鬱願選鏇糧艱鏇餘簾廠 ) 更多 | ||||||
临床1/2期 | 13 | nivolumab+CIMAvax-EGF | 廠網餘鑰選襯築鏇衊醖(遞蓋鑰廠鹽餘願憲憲觸) = 淵選窪願蓋製憲積築衊 蓋窪襯鹽醖壓鏇糧糧廠 (廠製選獵壓築夢糧餘願 ) 更多 | 积极 | 2022-08-03 | ||
N/A | - | 餘壓築鑰廠網築淵觸願(積鹹夢壓獵選顧範鑰繭) = 醖觸憲網顧製簾窪糧選 鹹遞簾簾糧艱鏇製衊簾 (顧簾遞製醖網積願廠醖 ) 更多 | - | 2019-09-09 | |||
N/A | 维持 | 106 | 壓願夢淵齋簾鑰構積構(築積簾餘範糧網齋餘築) = 7.3% 鑰獵築鏇膚醖窪顧壓蓋 (範網襯淵窪憲鏇鹽糧鑰 ) 更多 | - | 2019-09-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用